Current status of cytokine therapy in management of patients with metastatic renal cell carcinoma

Authors

  • Anil K. Kapoor Department of Surgery (Urology), McMaster University, Hamilton, Ont.
  • Sébastien J. Hotte Department of Oncology, Juravinski Cancer Centre, Hamilton, Ont.

DOI:

https://doi.org/10.5489/cuaj.65

Abstract

Cytokine therapy with interferon-a and interleukin-2 has arguably been the standard treatment for patients with metastatic renal cell carcinoma for more than 20 years. In this paper, the current evidence for the use of cytokine therapy in this patient population is discussed, including the significant toxicity associated with these agents. A low overall response rate and a marginal survival advantage are observed with interferon-a and interleukin-2; however,these therapies have significant toxicity and impair quality of life. Unlike thecurrent tyrosine-kinase inhibitors, complete tumour responses may be seen with interleukin-2, but again this therapy has significant morbidity and mortality.Newer anti-angiogenesis agents may be combined with current standard cytokinetherapy for patients with metastatic renal cell carcinoma.

Downloads

Download data is not yet available.

Downloads

Published

2012-12-11

How to Cite

Kapoor, A. K., & Hotte, S. J. (2012). Current status of cytokine therapy in management of patients with metastatic renal cell carcinoma. Canadian Urological Association Journal, 1(2S). https://doi.org/10.5489/cuaj.65

Issue

Vol. 1 No. 2S (2007): CUAJ June-Supplement 1

Section

Review

License

You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:

  • Post the Article on any Web site
  • Translate or authorize a translation of the Article
  • Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
  • Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.

The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.

You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.

The CUA also requires you to warrant the following:

  • That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
  • That all individuals who have made a substantive contribution to the article are acknowledged;
  • That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
  • That the Article does not libel or violate the privacy rights of any third party.